Zacks: Analysts Expect Pear Therapeutics, Inc. (NASDAQ:PEAR) to Post -$0.25 Earnings Per Share

Equities research analysts predict that Pear Therapeutics, Inc. (NASDAQ:PEARGet Rating) will post ($0.25) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Pear Therapeutics’ earnings. The company is expected to report its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Pear Therapeutics will report full year earnings of ($0.87) per share for the current fiscal year, with EPS estimates ranging from ($0.90) to ($0.83). For the next financial year, analysts forecast that the business will report earnings of ($0.72) per share, with EPS estimates ranging from ($0.95) to ($0.52). Zacks’ earnings per share calculations are an average based on a survey of analysts that that provide coverage for Pear Therapeutics.

Pear Therapeutics (NASDAQ:PEARGet Rating) last announced its quarterly earnings results on Monday, March 28th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.01). The firm had revenue of $1.32 million for the quarter.

A number of research firms recently issued reports on PEAR. Bank of America began coverage on shares of Pear Therapeutics in a report on Wednesday, January 26th. They issued a “neutral” rating on the stock. Citigroup raised their price objective on shares of Pear Therapeutics from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Tuesday. Chardan Capital dropped their price objective on shares of Pear Therapeutics from $16.00 to $13.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, Zacks Investment Research raised shares of Pear Therapeutics from a “hold” rating to a “buy” rating and set a $5.75 price objective on the stock in a report on Friday, April 1st. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $10.55.

Shares of PEAR traded down $0.04 on Friday, reaching $3.61. The company’s stock had a trading volume of 217,742 shares, compared to its average volume of 271,019. The company’s 50 day moving average price is $4.73. Pear Therapeutics has a 12-month low of $2.81 and a 12-month high of $14.60.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Arboretum Ventures Inc. bought a new stake in shares of Pear Therapeutics during the fourth quarter valued at approximately $67,326,000. Roble Belko & Company Inc bought a new stake in shares of Pear Therapeutics during the fourth quarter valued at approximately $28,000. 5AM Venture Management LLC bought a new stake in shares of Pear Therapeutics during the fourth quarter valued at approximately $115,517,000. BerganKDV Wealth Management LLC bought a new stake in shares of Pear Therapeutics during the fourth quarter valued at approximately $28,000. Finally, TB Alternative Assets Ltd. bought a new stake in shares of Pear Therapeutics during the fourth quarter valued at approximately $12,846,000. Institutional investors own 53.66% of the company’s stock.

Pear Therapeutics Company Profile (Get Rating)

Pear Therapeutics, Inc, a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia.

See Also

Get a free copy of the Zacks research report on Pear Therapeutics (PEAR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Pear Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pear Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.